retatrutide triple agonist weight loss trial Retatrutide, an Amazing Future for 🚨 Today, retatrutide, the GIP/GLP-1/glucagon

What sets retatrutide apart is its triple agonist approach, which means it acts on three hormone pathways in your body at the same time: GLP-1, GIP, and glucagon

Nearly 60% of people achieved at least 25% weight loss, and around 40% lost 30% or more of their body weight

TRIUMPH-1 Phase 3 obesity results, May 2026 TRIUMPH-4 and TRIUMPH Phase 3 programme dosing information

Lancet Diabetes Endocrinol 2016;4:1004-16.ArticlePubMed 121

The heart-rate cost is mostly the glucagon arm: GLP-1 on its own nudges heart rate up a little and then flattens, while glucagon carries the part that keeps climbing with the dose

GLP-1 plays a central role in appetite regulation, insulin secretion, blood sugar control, and even weight loss